Insys Therapeutics Inc

Most Recent

  • uploads///analysis _
    Company & Industry Overviews

    Why Insys Therapeutics Fell More than 70% Yesterday

    Insys Therapeutics (INSY) released its first-quarter earnings results on May 10.

    By Margaret Patrick
  • uploads///Insys therap
    Company & Industry Overviews

    How INSYS Therapeutics’ Earnings Were Trending

    In the first nine months of 2018, INSYS Therapeutics’ (INSY) net income and diluted EPS amounted to $78.1 million and $1.06, respectively.

    By Daniel Collins
  • uploads///INSY
    Company & Industry Overviews

    How Is INSYS Therapeutics Financially Positioned in January?

    In the first nine months of 2018, INSYS Therapeutics’ net revenues declined ~40% YoY to reach $109.2 million from $65.7 million.

    By Daniel Collins
  • uploads///flowers _
    Company & Industry Overviews

    Cannabis Stock INSYS Therapeutics Has Risen 28% in January

    On January 10, INSYS Therapeutics stock closed at $4.49, which represents ~28% growth from its stock price of $3.50 at the close of markets on December 31.

    By Daniel Collins
  • uploads///GW revenue
    Company & Industry Overviews

    A Look into GW Pharmaceuticals’ Revenue Trends

    In the fourth quarter of fiscal 2018, GW Pharmaceuticals (GWPH) generated revenues of $2.42 million compared to $2.45 million in the same period the prior year.

    By Daniel Collins
  • uploads///Chart XXII
    Company & Industry Overviews

    Analyzing 22nd Century Group’s Year-to-Date Performance

    Analysts expect 22nd Century Group to report revenue of $23.3 million in 2018, a 40.3% rise compared to $16.6 million in 2017.

    By Mike Benson
  • uploads///Chart Insys
    Company & Industry Overviews

    A Closer Look at Insys Therapeutics’ Performance Year-to-Date

    Insys Therapeutics (INSY) is among the specialty pharmaceutical companies that focus on developing cannabinoids and sprays.

    By Mike Benson
  • uploads///seedling _
    Company & Industry Overviews

    How Marijuana-Focused Biotech Companies Have Performed in 2018

    In this series, we’ll discuss analysts’ estimates, recommendations, and revenue estimates for marijuana biotechnology companies.

    By Mike Benson
  • uploads///marijuana _
    Healthcare

    Marijuana-Focused Biotech Companies in Q3: Are They Performing?

    In this series, we’ll look at biotechnology companies focused on marijuana-based products and how they performed in the third quarter.

    By Mike Benson
  • uploads///MJ Acceptance
    Company & Industry Overviews

    Vermont Legalizes Recreational Marijuana on January 22, 2018

    On January 22, Vermont decriminalized the possession of marijuana for adults 21 and older. Vermont became the ninth state to legalize marijuana for recreational purposes.

    By Adam Jones
  • uploads///MJ
    Healthcare

    The Other Side of Legalizing Recreational Marijuana

    While marijuana legalization for recreational use is just gaining attention around the world, it’s also facing strong opposition. According to some, legalizing marijuana will just increase substance abuse.

    By Adam Jones
  • uploads///Chart Title
    Basic Materials

    The Marijuana Ecosystem’s Potential Business Opportunities

    Given that legislative approval is the strongest driving factor behind the boost in the marijuana industry, companies have rushed to capitalize on the wave.

    By Adam Jones
  • uploads///Chart Title
    Basic Materials

    Is Investment in the Marijuana Space Picking Up?

    In the previous part of this series, we saw that the alcohol industry could expect marijuana legalization for recreational purposes as an extension to their growth strategy.

    By Adam Jones
  • uploads///Legalization
    Basic Materials

    How Marijuana Acceptance Is Evolving Globally

    It’s fascinating to see how the marijuana landscape around the world has evolved in the last three years. According to Canopy Growth (WEED.TO), Canada, Israel, the Czech Republic, Uruguay, and the Netherlands “established federally legal cannabis access regimes” in 2014.

    By Adam Jones
  • uploads/// Month Return
    Basic Materials

    Must-Knows before Investing in the Marijuana Industry

    In our recent series Should You Jump on the Marijuana Bandwagon? we briefly touched upon the marijuana industry from an investment perspective.

    By Adam Jones
  • uploads///Insys drugs pipeline january
    Company & Industry Overviews

    What Are Insys Therapeutics’ Top Priorities?

    Insys has brought new leadership on board with the appointment of Saeed Mohatari as the company’s new CEO and Andrew Long as the new CFO.

    By Kenneth Smith
  • uploads///Insys priorities
    Company & Industry Overviews

    Insys Has Legal Issues Galore

    In December 2016, the U.S. Attorney’s office for the District of Massachusetts issued an indictment against six former Insys (INSY) employees.

    By Kenneth Smith
  • uploads///Insys legal issues
    Company & Industry Overviews

    What’s behind Insys Therapeutics’ Legal Tangles?

    Insys received a subpoena in December 2013 from the inspector general of HHS for an investigation of potential violations that involved HHS programs.

    By Kenneth Smith
  • uploads///Areas Affected
    Healthcare

    Gauging Marijuana Risk: The Potential Investment Blowback

    Investing in the marijuana industry—at least in its current stage in the US—certainly comes with its own set of risks.

    By Adam Jones
  • uploads///Ana Reco Insys
    Company & Industry Overviews

    What Analysts Recommend for Insys Therapeutics and Peers

    Insys Therapeutics (INSY) is a commercial-stage specialty pharmaceutical company headquartered in Chandler, Arizona.

    By Kenneth Smith
  • uploads///Graph Part  Dec
    Company & Industry Overviews

    The SPDR S&P Biotech ETF Lingers in the Red as of December 3

    The SPDR S&P Biotech ETF (XBI) went down by 3.9% on December 3, which represents the third consecutive day of declines for the ETF. XBI closed at $68.91.

    By Peter Neil
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.